河北中医2026，Vol.48Issue(1)：16-21,6.DOI:10.3969/j.issn.1002-2619.2026.01.004
香砂六君子汤加减内服联合理气止痛散热熨治疗胃癌脾虚痰湿证腹胀痛的临床观察
Clinical efficacy of modified Xiangsha Liujunzi Decoction combined with Liqi Zhitong hot medicinal compress therapy in the treatment of abdominal distension and pain attributed to gastric cancer-associated spleen deficiency and phlegm-dampness
摘要
Abstract
Objective To evaluate the clinical efficacy of modified Xiangsha Liujunzi Decoction(mXLD)combined with Liqi Zhitong hot medicinal compress therapy(LZHMCT)in patients with abdominal distension and pain attributed to gastric cancer(GC)-associated spleen deficiency and phlegm dampness.Methods From January 2021 to October 2024,105 patients presenting with abdominal distension and pain attributed to GC-associated spleen deficiency and phlegm-dampness were enrolled in this study.Patients were randomly assigned,using a random number table,to the treatment group(n=35),control group 1(n=35),and control group 2(n=35).Patients in control group 1 received a standardized three-step treatment,while those in control group 2 received mXLD in addition to the standard treatment.Patients in the treatment group were treated with mXLD combined with LZHMCT.After three weeks of treatment,traditional Chinese medicine(TCM)syndrome-based efficacy,objective clinical efficacy,clinical efficacy,post-treatment pain intensity,onset and duration of pain relief,number of breakthrough pain episodes,severity of treatment-related toxicity,Karnofsky Performance Status(KPS)score,Zung Self-rating Depression Scale(SDS)score,and carcinoembryonic antigen(CEA)levels were compared among the three groups.Results The treatment group exhibited significantly higher overall TCM syndrome-based efficacy[94.29%(33/35)vs.65.71%(23/35)and 82.96%(29/35)],clinical objective efficacy[85.71%(30/35)vs.57.14%(20/35)and 71.43%(25/35)],and clinical efficacy[94.29%(34/35)vs.65.71%(25/35)and 82.96%(30/35)]compared with control groups 1 and 2(all P<0.05).Additionally,patients in the treatment group had significantly higher complete pain relief rate[77.14%(27/35)vs.28.57%(10/35)and 57.14%(20/35)],shorter time to onset of pain relief,longer duration of pain relief,and fewer breakthrough pain episodes compared to control groups 1 and 2(all P<0.05).KPS and SDS scores were markedly increased while serum CEA levels were decreased following treatment in all three groups(all P<0.05).Furthermore,the treatment group showed significantly higher KPS and SDS scores,lower serum CEA levels,and lower severity of treatment-related toxicity compared to the control groups(all P<0.05).Conclusion mXLD combined with LZHMCT is effective for managing abdominal distension and pain attributed to GC-associated spleen deficiency and phlegm-dampness.This combination regimen provides faster and longer-lasting pain relief,reduces the frequency of breakthrough pain,improves quality of life and emotional well-being,lowers CEA levels,and mitigates treatment-related toxicities.关键词
胃癌/脾虚痰湿型腹胀痛/香砂六君子汤/理气止痛散/热熨治疗Key words
Gastric cancer/Abdominal distension and pain attributed to spleen deficiency and phlegm dampness/Xiangsha Liujunzi Decoction/Liqi Zhitong Powder/Hot medicinal compress therapy分类
医药卫生引用本文复制引用
赵慧,张曦尧,钱美芬,王坚..香砂六君子汤加减内服联合理气止痛散热熨治疗胃癌脾虚痰湿证腹胀痛的临床观察[J].河北中医,2026,48(1):16-21,6.基金项目
宜兴市卫生健康委员会科技项目(编号:yxfc09) （编号:yxfc09）
